Overview

Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

Status:
Completed
Trial end date:
2011-04-08
Target enrollment:
Participant gender:
Summary
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period. This study will also evaluate the safety and tolerability of telcagepant for female migraine participants.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.